Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype.

Blood - 1 Dec 1996

Ben-Yehuda D, Krichevsky S, Caspi O, Rund D, Polliack A, Abeliovich D, Zelig O, Yahalom V, Paltiel O, Or R, Peretz T, Ben-Neriah S, Yehuda O, Rachmilewitz E A

Abstract excerpt

During the last decade the frequency of therapy-related acute leukemia (t-leuk) and myelodysplastic syndrome (t-MDS) has been increasingly observed. Over the past 15 years, we treated 56 patients with t-leuk who had received prior chemotherapy (39%), radiotherapy (11%), or both (45%). The drugs r...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age of Onset
Share to Antineoplastic Agents
Share to DNA Damage

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mutational Analysis

Share to Drug Resistance, Multiple

Share to Drug Resistance, Neoplasm

Share to Genes, p53

Share to Microsatellite Repeats

Source

Identifiers

PMID: 8943866

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-8943866-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype.PMID 8943866Read ↗

TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.Semantic proximity Read ↗

The Role Of Early TP53 Mutations On The Evolution Of Therapy-Related AMLSemantic proximity Read ↗

Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.Semantic proximity Read ↗

The p53 gene in pediatric therapy-related leukemia and myelodysplasia.Semantic proximity Read ↗

Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?Semantic proximity Read ↗

Mutations With Loss of Heterozygosity of p53 Are Common in Therapy-Related Myelodysplasia and Acute Myeloid Leukemia After Exposure to Alkylating Agents and Significantly Associated With Deletion or Loss of 5q, a Complex Karyotype, and a Poor PrognosisSemantic proximity Read ↗

Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotypeSemantic proximity Read ↗

High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome.Semantic proximity Read ↗

The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia.Semantic proximity Read ↗

Defective DNA-mismatch repair: a potential mediator of leukemogenic susceptibility in therapy-related myelodysplasia and leukemia.Semantic proximity Read ↗

Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents.Semantic proximity Read ↗

Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.